Impact of immature platelets and erythrocytes on clinical risk stratification of patients with atrial fibrilation

Impact of immature platelets and erythrocytes on clinical risk stratification of patients with atrial fibrilation - PRISCA-AF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023100

Enrollment

2000

Registered

2020-10-01

Start date

2020-09-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I48

Interventions

Group 1: patients with atrial fibrillation will be contacted after 12 month and questioned about bleeding and ischemic events

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: men and women of at least 18 years of age with proven diagnosis of atrial fibrillation (at least one ECG document) with or without the indication for oral anticoagulation

Exclusion criteria

Exclusion criteria: missing laboratory parameters (IP, RetHe), people working for the institution, people with severe psychiatric disease or other desease making it impossible to collect valid answers after 12 month

Design outcomes

Primary

Measure	Time frame
clinically relevant bleeding complications (defined as BARC =2) or ischemic events after 12 month	—

Secondary

Measure	Time frame
death of any cause, non-fatal myocardial infarction	—

Countries

Germany

Contacts

Public ContactAlexander Kille

Universitätsherzzentrum

alexander.kille@universitaets-herzzentrum.de07633 402 0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026